XML 37 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8
SELECTED QUARTERLY INFORMATION - UNAUDITED (Tables)
 12 Months Ended
Dec. 31, 2013
Selected Quarterly Financial Information [Abstract]  
Selected Quarterly Information
 
First Quarter
 
Second Quarter
 
Third Quarter
 
Fourth Quarter
 
(In thousands, except per share data)
Total revenue, net:
 
 
 
 
 
 
 
2013
$
196,652

 
$
205,547

 
$
213,246

 
$
220,769

2012
196,185

 
210,170

 
210,084

 
214,432

Gross margin:
 
 
 
 
 
 
 
2013
$
116,384

 
$
122,479

 
$
129,145

 
$
134,121

2012
121,510

 
131,896

 
130,536

 
132,502

Net income (loss):
 
 
 
 
 
 
 
2013 (1)
$
(4,050
)
 
$
3,440

 
$
(28,550
)
 
$
12,183

2012
6,693

 
8,514

 
13,211

 
12,786

Basic net income (loss) per common share (2):
 
 
 
 
 
 
 
2013
$
(0.15
)
 
$
0.12

 
$
(1.02
)
 
$
0.40

2012
0.24

 
0.30

 
0.46

 
0.46

Diluted net income (loss) per common share (2):
 
 
 
 
 
 
 
2013
$
(0.15
)
 
$
0.12

 
$
(1.02
)
 
$
0.40

2012
0.23

 
0.30

 
0.46

 
0.46


(1) The first quarter of 2013 was negatively impacted by a voluntary recall of certain products manufactured in the Company's Añasco, Puerto Rico facility.
On July 31, 2013, the Company performed the annual goodwill impairment test which resulted in a non-cash goodwill impairment charge of $46.7 million for its U.S. Spine reporting unit, which is a part of the U.S. Spine and Other reportable segment.
The Company incurred incremental costs related to the implementation of its global enterprise resource planning system in the first, second, third, and fourth quarters of 2013 of $6.1 million, $7.6 million, $5.0 million and $5.6 million, respectively.

The Company incurred costs related to the remediation of the FDA warning letters at its manufacturing facilities of $2.1 million, $3.0 million, $2.8 million and $0.4 million in the first, second, third and fourth quarters of 2013, respectively.
(2) Per common share amounts for the quarters and full years have been calculated separately. Accordingly, quarterly amounts do not necessarily add to the annual amount because of differences in the weighted average common shares outstanding during each period principally due to the effect of the Company’s issuing shares of its common stock during the year.